top of page
A NOVEL APPROACH TO
AIRWAY DISEASES
Find out more about our unique therapeutic strategy
Our non-antibiotic macrolide platform addresses epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases.
Home: Products
Tackling one of the world's most prevalent diseases
Chronic obstructive pulmonary disease (COPD) afflicts more than a quarter of a billion people globally, leading to more than 3 million deaths every year.
The unmet need for disease-modifying therapies for COPD
There are no clinical trials showing that any existing medications for COPD modify the long-term decline in lung function that characterizes COPD.
A new paradigm of epithelial barrier insufficiency
Find out more about our unique approach targeting epithelial barrier insufficiency as a key driver of inflammation in chronic respiratory diseases.
LATEST NEWS
CONTACT US
Contact
SEND US A MESSAGE
bottom of page